ASCO 2025 Highlights | IASLC
This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe …
Related Articles
Welcome! You are invited to join a webinar: Post-ASCO 2025 Lung Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
Virtual Tumor Board: Targeting Residual Disease | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and…
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib | JCO Precision Oncology
PURPOSEORCHARD (ClinicalTrials.gov identifier: NCT03944772) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients with epidermal…
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Rearrangements of the lung adenocarcinoma gene creating oncogenic fusions in anaplastic lymphoma kinase (ALK), of which the most common is echinoderm microtubule-associated protein-like 4 (EML4),…
A Phase II Study of Cabozantinib in Patients with MET-Altered Lung Cancers
Only type I MET tyrosine kinase inhibitors (TKIs) are approved for treating MET-altered non-small cell lung cancers (NSCLCs). Preclinically, type II TKIs like cabozantinib can…
ASCO 2025 Highlights | IASLC
This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe…
Welcome! You are invited to join a webinar: Post-ASCO 2025 Lung Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report
The PHAROS primary analysis showed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report…
Welcome! You are invited to join a webinar: Post-ASCO 2025 Lung Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar featuring presentations & discussions on selected abstracts in lung cancer from ASCO 2025. Chaired by Noemí Reguart Moderated by Stephen Liu, Nicolas Girard…
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
Treatment-free survival (TFS) characterizes periods of disease control and durable clinical benefit following treatment discontinuation in patients treated with immunotherapy. In CheckMate 227 Part 1,…